RxDoctor Payments Data

Charles Idom

Urology · Dalton, GANPI 1316943210

Payments from drug & device makers

$13,640in general payments, 2019–2025

Across 419 payments — averaging $32.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$4K
  • Axonics, Inc.$1K
  • Medtronic$1K
  • Procept Biorobotics Corporation$703
  • Dendreon Pharmaceuticals LLC$674
  • Pfizer$554
  • plus $6K from 47 others

What the payments were for

  • Speaking & faculty fees$4733%
  • Travel & lodging$3,42125%
  • Food & beverage$9,62071%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,640 in reported general payments places this provider in the 80th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$918,606
Medicare patients
691
Services billed
21,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide120$1,670,816
OrgovyxRelugolix151$391,391
LynparzaOlaparib22$360,141
NubeqaDarolutamide24$317,516
MyrbetriqMirabegron50$39,951
GemtesaVibegron33$24,052
Tamsulosin Hcl192$3,324
Testosterone26$3,122
Finasteride177$2,586
Methenamine Hippurate32$2,271
Alfuzosin Hcl ErAlfuzosin Hcl94$1,920
Dutasteride42$1,897
Testosterone Cypionate14$759
Oxybutynin Chloride ErOxybutynin Chloride32$473
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$544$1,710,767170 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$392$415,442184 claims
AstraZenecaLynparza$353$360,14122 claims
BayerNubeqa$475$317,51624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 369 urology providers in Georgia.

Other urology in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →